Mitochondrial disorders leading to Alzheimer's disease-perspectives of diagnosis and treatment

Geroscience. 2024 Jun;46(3):2977-2988. doi: 10.1007/s11357-024-01118-y. Epub 2024 Mar 8.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia globally. The pathogenesis of AD remains still unclear. The three main features of AD are extracellular deposits of amyloid beta (Aβ) plaque, accumulation of abnormal formation hyper-phosphorylated tau protein, and neuronal loss. Mitochondrial impairment plays an important role in the pathogenesis of AD. There are problems with decreased activity of multiple complexes, disturbed mitochondrial fusion, and fission or formation of reactive oxygen species (ROS). Moreover, mitochondrial transport is impaired in AD. Mouse models in many research show disruptions in anterograde and retrograde transport. Both mitochondrial transportation and network impairment have a huge impact on synapse loss and, as a result, cognitive impairment. One of the very serious problems in AD is also disruption of insulin signaling which impairs mitochondrial Aβ removal.Discovering precise mechanisms leading to AD enables us to find new treatment possibilities. Recent studies indicate the positive influence of metformin or antioxidants such as MitoQ, SS-31, SkQ, MitoApo, MitoTEMPO, and MitoVitE on mitochondrial functioning and hence prevent cognitive decline. Impairments in mitochondrial fission may be treated with mitochondrial division inhibitor-1 or ceramide.

Keywords: Alzheimer’s disease; Antioxidants; MitoQ; Mitochondrial dysfunction; Oxidative stress; ROS.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / etiology
  • Alzheimer Disease* / therapy
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Antioxidants
  • Mice
  • Mitochondria / metabolism
  • Mitochondrial Diseases* / metabolism

Substances

  • Amyloid beta-Peptides
  • Antioxidants